FDA Approves First Oral PCSK9 Inhibitor - Poll - MDSpire

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 2 min

Share

Original Source(s)

FDA Approves First Oral PCSK9 Inhibitor

  • by Kathryn Wighton

  • July 16, 2026

Related Content

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.

Association between the fibrosis-4 index and carotid atherosclerosis in Chinese patients with type 2 diabetes mellitus: a cross-sectional study